Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma.
Alexander Chehrazi-RaffleRamya MuddasaniNazli DizmanJoAnn HsuLuis MezaZeynep B ZenginJasnoor MalhotraNeal ChawlaTanya DorffTania Contente-CuomoDevin DinwiddieBradon R McDonaldTimothy McDanielJeffery M TrentFrederick L BaehnerMuhammed MurtazaSumanta Kumar PalPublished in: JCO precision oncology (2023)
In this pilot study, TARDIS accurately differentiated PR from CR among patients with mRCC receiving immunotherapy, and also prospectively identified patients at risk for subsequent progression. Given these findings, we envision subsequent studies that validate these results and investigate the utility of this assay to discern appropriate candidates for discontinuation of immunotherapy.
Keyphrases